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 Newborn screening is used to diagnose illness in presymptomatic infants so that they may 
begin intervention to reduce the impact of the illness. The Recommended Universal Screening 
Panel (RUSP) is a list of conditions designated by a national panel to guide newborn screening in 
all states; this testing is currently conducted predominantly by tandem mass spectrometry to 
detect analytes indicative of rare inborn errors of metabolism.  Advances in genetic sequencing 
technology now enable us to consider the possibility of using sequencing as a way to 
presymptomatically identify a vast number of other rare Mendelian conditions.  However, if 
genetic screening is to be used to expand newborn screening, a low cost method must be found to 
accomplish this task.  
Our research group is currently considering Molecular Inversion Probes (MIPs) to 
complete this task. MIPs are being designed to target RUSP conditions which have already been 
vetted for return to patients, and evaluation of their performance in genes causing primary RUSP 
conditions is being considered the first step in evaluating their use in newborn screening.   We 
designed MIPs to cover 40 such genes and sequenced 8 individuals to evaluate their 
performance. To review the performance of MIPs, the percent of known pathogenic variants 
within a given gene with MIPs designed to detect them as well as the percent of known 
pathogenic variants with at least 30X depth in all 8 samples was determined using the ClinVar 
database and the University of California, Santa Cruz genome browser (HG38). It was found that 
for some genes, MIPs were capable of detecting corresponding pathogenic variants, while for 
other genes, MIPs would miss some or all of the known pathogenic variants. A targeted search of 
which pathogenic variants were missed could help evaluate MIPs that need to be redesigned 
before the assay can be used to supplement newborn screening, in order to validate this genetic 
test to try and optimize it for use in newborn screening. Our goal is to find an affordable method 
for genetic testing which may be used to expand newborn screening far beyond the scope of the 




         Newborn screening is important to detect severe or life-threatening illness in 
presymptomatic infants so that management of the illness may begin as soon as possible in order 
to reduce the impact of the illness. However, it is critical to first ask if we should screen for a 
disorder in a presumably healthy infant just because we can. Wilson and Jungner came up with 
the first guideline to help answer this question in 1968.1 Outlining several criteria including: 
availability of a reasonably-priced test, a well-known natural history, an established treatment 
policy, and an accepted treatment.1 It should also be recognizable before it is problematic, and 
there must be health-care facilities available to diagnose and treat the condition.1 This has 
remained the gold standard when determining which conditions should be included in any 
screening program, such as newborn screening. 
         Newborn screening began in the 1960s when it became possible to test for 
phenylketonuria (PKU), which is an autosomal recessive condition caused by phenylalanine 
hydroxylase (PAH) deficiency.2 Individuals with PKU develop hyperphenylalaninemia. The 
PAH enzyme normally converts phenylalanine to tyrosine, and loss of the enzyme results in 
buildup of phenylalanine, which is neurotoxic in high quantities in the brain.2 This understanding 
of the basic biochemical defect led to the discovery that PKU can be treated, with early 
detection, by removing phenylalanine from the diet to prevent neurological damage.2 Thus, PKU 
became an ideal candidate for newborn screening.   
Over time, the ability to test for rare genetic conditions in newborns has increased. 
Notably, tandem mass spectrometry (MS/MS) has allowed for the detection of hundreds of 
biochemical markers, so that multiple inborn errors of metabolism can be detected at birth. 
However, there was no national consensus on what to include in newborn screening and some 
states expanded screening more than others. To address this issue, the Maternal and Child Health 
Bureau of the Health Resources and Administration commissioned the American College of 
Medical Genetics to develop nationally recognized newborn screening standards and policies in 
1999.3 This included a recommended uniform screening panel (RUSP), which was to guide state 
newborn screening programs.3 RUSP conditions were scored based on many criteria including: 
the ability to identify the signs and symptoms within the first 48 hours of life, characteristics of 
the test, burden of the disease, availability and cost of treatment, burdens and benefits of early 
intervention, and the incidence of the condition.3 Primary RUSP conditions are those 
recommended explicitly for newborn screening, while secondary RUSP conditions represent 
conditions that may be detected from the same tests as the primary RUSP conditions. They may 
have similar clinical features to the primary RUSP conditions; however, they are usually rarer 
and have less known treatments and interventions. There are currently 34 primary and 26 
secondary RUSP conditions.4 Despite the existence of the RUSP, newborn screening is still 
regulated at the state level 5 and additional conditions may be included in newborn screening 
based on state laws, cost of screening, frequency of the condition in the state, availability of 
treatment, and funding given to the newborn screening program.5 
         As seen with MS/MS, genome-scale sequencing could increase the number of conditions 
that could be included in newborn screening exponentially.6 Genome-wide sequencing has 
allowed us to detect and discover new disease genes; however, what we know about the causal 
genetic variants may be limited and our ability to intervene presymptomatically may be quite 
limited. Thus, it is important to establish criteria for determining which genes should be included 
in newborn screening.6 
         The North Carolina Newborn Exome Sequencing for Universal Screening (NC NEXUS) 
project is part of a national cooperative to evaluate the potential to use exome sequencing in 
newborn screening programs.7 NC NEXUS hopes to establish a framework to identify medically 
actionable gene-disease pairs that could be included in newborn screening to allow for early 
monitoring and treatment. While NC NEXUS originally considered the scenario in which 
genome-scale sequencing might be utilized for newborn screening, there are numerous technical, 
clinical, and societal challenges to this concept; members of the NC NEXUS team are concerned 
that it may be too problematic for large-scale implementation at this time. However, our research 
group hopes that by studying massively parallel sequencing for use in genomic screening, its 
strengths and limitations for use in newborns can be elucidated. 
 There is concern that returning all of the gene-disease pairs at once could impair parental 
bonding, create “patients-in-waiting,” and impinge on the ability of the child to make their own 
healthcare decisions in the future. 8 Our research group believes that breaking targeted 
sequencing up into age-based panels mapped to routine childhood care may help avoid some of 
these pitfalls of genome-scale sequencing, and could facilitate the gradual provision of 
educational materials, staged informed consent, and delivery of age-based genomic screening.8   
 Our research group is currently evaluating molecular inversion probes (MIPs) as an 
alternative to hybridization-based RNA probes for targeted sequencing. Both approaches can be 
designed so that unique barcodes allow for identification of individual samples after they are 
combined, and the pooling of samples reduces overall sequencing costs. In sequencing, only a 
certain amount of sequence data can be generated per flow cell. The more samples that can be 
pooled into one flow cell, the lower the cost of sequencing per sample. Exome sequencing, 
which targets the expressed regions of all ~20,000 genes, looks at a larger portion of the genome 
per sample, so only a few samples can be pooled to obtain the ideal 30X coverage. With an 
approach that targets fewer than 100-200 genes, much less sequence data is required to be 
generated per sample, so we can pool many more samples together and greatly reduce the 
sequencing cost per sample while still allowing for 30X coverage.  Although targeted sequencing 
could also be carried out using RNA hybridization probes, they are more expensive to synthesize 
than MIPs, which are DNA oligonucleotide probes that can be generated at scales that allow 
thousands of samples to be analyzed with a single fixed cost for the assay. 
In addition to targeting genes for the RUSP, we envision that MIPs could also be selected 
to form targeted age-based panels, so that screening for genetically inherited diseases could 
occur as they become relevant to the child. Distributing information in this fashion would limit 
the results returned to the child’s caregivers at any one time, and help prevent information 
overload and worry about health issues that will likely not arise until later on.8 
A first step to evaluating the viability of MIPs in expanded newborn screening is to 
examine their ability to test for RUSP conditions, which would presumably not require an in 
depth informed consent process, as parents will receive information that is already being 
routinely generated for all newborns. Pairing DNA sequencing with traditional MS/MS screening 
methods can improve the sensitivity and specificity for detecting RUSP conditions, and knowing 
the genetic basis for the condition may help parents understand their own carrier status to help 
them make informed decisions about future children. In some cases, genetic sequencing results 
may help guide management or treatment options. For example, some variants are associated 
with more severe or mild forms of the condition and could help the child’s caregivers understand 
the course the condition is likely to take so that appropriate cautionary measures can be taken. In 
other cases, variants may be associated with the effectiveness of a given treatment and may allow 
for selection of a treatment that will be of the greatest benefit to the child.  
 
Methods 
  We first generated a panel of MIPs through 
a commercial vendor, NimbleGen.  The list of 40 genes 
associated with the primary RUSP conditions was 
generated using OMIM, Gene Reviews, and OrphaNet. 
An online tool called NimbleDesign was used to design 
a panel of MIPs to cover these genes. Technicians in the 
lab uploaded each gene into NimbleDesign and the 
protein coding regions were selected for HG38, the 
latest iteration of the human reference genome. Each 
MIP had already been designed and tested in 
NimbleGen’s lab.  
 The selected MIPs were pooled together and 
optimized according to NimbleGen’s proprietary 
protocol. Samples from 8 participants in a previous study called NCGENES (who had already 
undergone whole-exome sequencing) were used to test the RUSP MIP design. Samples were 
prepared using the HEAT-Seq protocol (Figure 1). 9 Once the MIPs are hybridized to their target 
regions in the genomic DNA, extension and ligation steps are used to generate a circular 
template. Non-targeted linear DNA is digested using exonuclease, and the targeted regions 
provide a template for PCR amplification. The samples were then pooled and sequenced on the 
MiSeq platform.   
 Using the pipeline recommended by the manufacturer, samples were processed and 
analyzed to determine the coverage for each probe after deduplication of capture events. The 
probes were then color-coded based on their coverage and visualized on the University of 
California, Santa Cruz (UCSC) genome browser. The UCSC genome browser allows users to 
load  a wide range of annotation “tracks” that help to identify genes, transcripts, and variants, as 
well as user-defined custom tracks which can be stacked to enable visualization and analysis.10  
 Since the purpose of the MIP design is to screen for clinically relevant variants, we 
focused, in this analysis, on the ability of the assay to identify pathogenic variants in genes 
causing primary RUSP conditions.  We reasoned that this analysis would identify potential 
problem areas that might require further optimization or redesign. Pathogenic and likely 
pathogenic variants within each gene were identified using ClinVar, a publically available 
database of variants and their associated phenotypes from scientific literature.11 These assertions 
are made by a range of different submitters, including clinical laboratories, researchers, or other 
databases (such as OMIM). Interpretations of the clinical significance may be one of the 
following: pathogenic, likely pathogenic, variant of uncertain significance, likely benign, or 
benign.11 However, since ClinVar accepts multiple assertions about the same variant by different 
submitters, with differing levels of review (some submitters do not provide criteria for their 
assertions), there can be variants with “conflicting” assertions.11 Therefore, I only included 
pathogenic or likely pathogenic variants for which the submitter had included criteria for 
inclusion and for which there were no conflicting assertions. I loaded a custom track containing 
the location of each MIP in the RUSP design and showed the level of coverage in the 8 samples. 
I then looked up the location for each variant found in ClinVar on the UCSC genome browser, 
and visually assessed for the presence of a MIP and the depth of coverage of that MIP. I recorded 
the number of variants in each gene that would be within the MIP design and therefore 
potentially detectable (referred to subsequently as Design Coverage) and the number of these 
variants for which there was at least 30X coverage for each participant (referred to subsequently 
as Design Performance). An average depth of 30 reads is generally regarded as a genome-wide 
benchmark to ensure adequate coverage to differentiate between homozygous or heterozygous 
variants, which would be important for determining carrier status or the presence of a 
homozygous recessive condition.  
 
Results 
 The performance of the MIPs on the RUSP panel was evaluated by their potential ability 
to detect pathogenic variants in the 40 genes associated with primary RUSP conditions. For 3 of 
these genes, HMGCS1, SLC5A5, and THRA, their only documented causes that met our criteria 
for inclusion were copy number changes. The MIP assay was not designed to detect such 
changes, so these were excluded from further analysis. 28 of the remaining 37 genes had a design 
coverage of 100%, while 9 had a design coverage of 90% or above (Table 1).  Thus, the MIP 
assay, if it performed perfectly, would cover 1277 out of 1296 (98.5%) variants in the RUSP 
genes.  In the 8 samples that we analyzed, design performance was more varied, with 18 genes 
having adequate coverage of 100% of variants, 3 genes having >90% of variants covered, and 4 
genes with >75% of variants covered. The remaining 12 genes had fewer than 50% of the 
variants covered at 30X in all samples (Table 1).  Overall, 98.5% of pathogenic variants had at 
least 1 MIP designed to detect them, and 62.6% of the pathogenic variants with MIPs designed to 
detect them had at least 1 MIP with 30X coverage in all 8 samples (Figure 2).   
 
 A critical factor in assessing the clinical sensitivity of a genetic test is to determine 
whether the most common pathogenic variants would be detected, since they will impact more 
people. An example of this analysis was carried out for Maple Syrup Urine Disease (MSUD) 
which has three genes associated with it: BCKDHA, BCKDHB, and DBT. BCKDHA had MIPs 
designed to detect all of the pathogenic variants located within it; however, only 2 out of the 36 
pathogenic variants were covered by a MIP with at least 30X coverage for each of the 8 
participants (Table 1). The most common variant, which accounts for 45% of MSUD cases, is 
located in BCKDHA. 12 Out of 8 participants, this variant is covered by a MIP that achieved at 
least 30X coverage for 4 participants, and between 10-29X for the other 4 participants. The next 
most common variants are located in the gene BCKDHB, and would be covered by at least 1 MIP 
with 30X coverage in all 8 participants.12 Since BCKDHA, BCKDHB, and DBT all had MIPs 
designed to cover all pathogenic variants located within the gene, this suggests that optimizing 
MIPs for better performance in BCKDHA would be critical to ensure that the most common 






















Biotinidase Deficiency BTD 61/61 61/61 
Long-chain L-3 Hydroxyl-CoA Dehydrogenase Deficiency HADHA 15/15 15/15 
Trifunctional Protein Deficiency HADHB 9/9 9/9 
3-Hydroxy-3-Methyglutaric Aciduria HMGCS2 4/4 4/4 
3-Methylcrotonyl-CoA Carboxylase Deficiency MCCC2 11/11 11/11 
Methylmalonic Acidemia (Cobalamin disorders) MMAA 26/26 26/26 
Homocystinuria MTR 3/3 3/3 
Homocystinuria MTRR 2/2 2/2 
Primary Congenital Hypothyroidism NKX2-5 15/15 15/15 
Classic Phenylketonuria PAH 146/146 146/146 
Primary Congenital Hypothyroidism PAX8 1/1 1/1 
Propionic Acidemia PCCB 25/25 25/25 
Primary Congenital Hypothyroidism  TSHB 1/1 1/1 
Primary Congenital Hypothyroidism  TSHR 7/7 7/7 
Medium-chain Acyl-CoA Dehydrogenase Deficiency ACADM 78/78 72/78 
Maple Syrup Urine Disease DBT 22/22 20/22 
Maple Syrup Urine Disease BCKDHB 56/56 48/56 
Isovaleric Acidemia IVD 28/28 24/28 
Carnitine Uptake Defect/Carnitine Transport Defect SLC22A5 63/63 52/63 
Tyroseinemia, Type I FAH 32/32 24/32 
Primary Congenital Hypothyroidism DUOXA2 2/2 1/2 
Primary Congenital Hypothyroidism DUOX2 14/14 4/14 
Glutaric Acidemia Type I GCDH 53/53 14/53 
Very Long-chain Acyl-CoA Dehydrogenase Deficiency ACADVL 87/87 17/87 
Argininosuccinic Aciduria ASL 30/30 3/30 
Maple Syrup Urine Disease BCKDHA 36/36 2/36 
3-Hydroxy-3-Methyglutaric Aciduria MMAB 8/8 0/8 
Homocystinuria MTHFR 1/1 0/1 
Homocystinuria CBS 61/62 4/61 
Glycogen Storage Disease Type II GAA 119/121 10/119 
Methylmalonic Acidemia (Methylmalonyl-CoA mutase) MUT 74/76 74/74 
Propionic Acidemia PCCA 31/32 29/31 
3-Methylcrotonyl-CoA Carboxylase Deficiency MCCC1 19/20 19/19 
Citrullinemia, Type I ASS1 35/37 15/35 
β- Ketothiolase Deficiency ACAT1 15/16 15/15 
Holocarboxylase Synthase Deficiency HLCS 12/13 12/12 
Classic Galactosemia GALT 75/83 31/75 
Methylmalonic Acidemia (Cobalamin disorders) HMGCS1 0/0 0/0 
Primary Congenital Hypothyroidism SLC5A5 0/0 0/0 
Primary Congenital Hypothyroidism THRA 0/0 0/0 
Table 1. Design coverage and performance for each gene corresponding to primary RUSP conditions. 
1 Design coverage is the number of pathogenic variants with at least 1 MIP designed to detect them over 
the total number of pathogenic variants within the gene. 
2 Design performance is the number of pathogenic variants with at least 1 MIP with 30X coverage for all 
8 participants over the total number of pathogenic variants capable of being detected by the MIPs.  
Discussion 
 We have explored the potential use of targeted sequencing using MIPs for primary RUSP 
conditions by looking at the percentage of pathogenic variants they are designed to cover and 
could potentially detect. Ideally each pathogenic variant would have a MIP designed to cover it 
and consistently have at least 30X coverage in all samples. However, 30X coverage is an 
arbitrary value, and lower coverage, such as 8X or 10X, might be sufficient to detect variants 
within the MIP, albeit not as reliably.  Although 30X is the average coverage one would wish to 
see across the entire genome, setting a single threshold of 30X coverage for each MIP in each 
participant is probably too stringent a guideline in evaluating the performance of the MIPs. A 
more inclusive alternative would be to evaluate MIPs on the average coverage for each MIP 
across all 8 participants. This would give a better picture of how well each MIP performed 
overall. Another metric to evaluate the performance of the MIPs would be to compare the 
variants called in the samples based on MIP targeted sequencing to the set of variants 
identified by whole-exome sequencing previously done on the samples. It is important to keep in 
mind that for population screening, the ability to detect the most prevalent disease-causing 
mutations may be sufficient, if they account for a large fraction of all cases. For this reason, it 
will be important to address the issue of which mutations are being captured, as well as overall 
success of capture.  
  
Conclusions and Future Directions 
 MIPs represent a viable strategy for targeted sequencing of primary RUSP conditions in 
newborns; however, they should be optimized to detect pathogenic variants as consistently as 
possible before they are used in newborn screening.  A different assay would need to be 
considered for HMGCS1, SLC5A5, and THRA which had no MIPs designed to detect pathogenic 
variants within them because the current set of probes is not designed to detect copy number 
variants. For genes, like GALT, with some pathogenic or likely pathogenic variants not covered 
in the MIP design, new MIPs should be designed and included in the assay, considering the 
trade-off on whether those variants are really critical to capture. For genes, like BCKDHA, with 
MIPs designed to detect pathogenic or likely pathogenic variants but which demonstrated lower 
coverage, optimization could involve rebalancing the concentration of that MIP in the assay or 
sequencing to a higher depth of coverage. For example, using HiSeq instead of MiSeq for 
sequencing would increase the number of reads per run for each region. Some of the poorly 
performing MIPs may be located in GC rich areas or may bind to pseudogenes. Either situation 
would lead to decreased capture by the MIP, and redesign may not be possible. Adding DMSO 
(Dimethyl Sulfoxide), a solvent which helps separate GC rich areas of the genome during 
denaturing, may aid in MIP capture in these regions. If this were able to increase average 
coverage for each MIP, then the number of MIPs that appeared to perform poorly using the 30X 
coverage metric might decrease. If not, then another method may need to be considered to 
capture variants within poorly performing MIPs. 
 Optimizing MIPs for use in newborn screening could allow for cost-effective population 
testing of genetic diseases to allow management of the illness as soon as possible in order to 
reduce the impact of the illness. MIPs could eventually be used in age-based screening to allow 
detection of conditions relevant to a child’s stage in development enabling the gradual provision 
of educational material and prevent information overload for the patient and their parents as they 
try to make decisions about their health.  
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